Comparing Akari Therapeutics PLC (AKTX) & Insys Therapeutics (INSY)
Akari Therapeutics PLC (NASDAQ: AKTX) and Insys Therapeutics (NASDAQ:INSY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.
This is a summary of recent recommendations and price targets for Akari Therapeutics PLC and Insys Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Akari Therapeutics PLC||0||1||2||0||2.67|
Akari Therapeutics PLC presently has a consensus price target of $8.75, indicating a potential upside of 92.73%. Insys Therapeutics has a consensus price target of $12.67, indicating a potential upside of 66.45%. Given Akari Therapeutics PLC’s stronger consensus rating and higher possible upside, research analysts plainly believe Akari Therapeutics PLC is more favorable than Insys Therapeutics.
Institutional and Insider Ownership
26.9% of Akari Therapeutics PLC shares are owned by institutional investors. Comparatively, 25.4% of Insys Therapeutics shares are owned by institutional investors. 61.8% of Akari Therapeutics PLC shares are owned by company insiders. Comparatively, 67.9% of Insys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Akari Therapeutics PLC and Insys Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Akari Therapeutics PLC||N/A||N/A||-$31.46 million||($0.18)||-25.22|
|Insys Therapeutics||$191.17 million||2.89||-$8.73 million||($0.25)||-30.44|
Insys Therapeutics has higher revenue and earnings than Akari Therapeutics PLC. Insys Therapeutics is trading at a lower price-to-earnings ratio than Akari Therapeutics PLC, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Akari Therapeutics PLC has a beta of -9.15, suggesting that its share price is 1,015% less volatile than the S&P 500. Comparatively, Insys Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500.
This table compares Akari Therapeutics PLC and Insys Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Akari Therapeutics PLC||N/A||-77.39%||-55.94%|
Insys Therapeutics beats Akari Therapeutics PLC on 6 of the 11 factors compared between the two stocks.
About Akari Therapeutics PLC
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. Its lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9. Coversin is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response. It is conducting Phase Ib clinical trial of Coversin. It focuses on rare and orphan diseases, including disease states spanning hematology, nephrology, transplantation, neurology and ophthalmology.
About Insys Therapeutics
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company’s lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.
Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.